Navigation Links
Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
Date:4/28/2011

EAST BRUNSWICK, N.J., April 28, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that three abstracts will be presented at the European League Against Rheumatism (EULAR) 2011 Annual Congress.  The conference will take place on May 25 - 28 in London, United Kingdom, and will feature the abstracts as two oral presentations and one poster presentation.

The first scheduled oral presentation and the poster session will address the prevalence of gout in Europe and current treatment practices and disease burdens for European gout patients using existing therapies. The second oral presentation will focus on long-term safety of KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.  The presentation details are as follows:

  • Chronic Gout in Europe in 2010: Clinical Profile of 1,380 Patients in the U.K., Germany, France, Italy and Spain (Abstract # OP0112). This abstract will be presented in an oral presentation on Thursday, May 26, 2011 at 11:10 AM.
  • Safety and Efficacy of Long-Term Pegloticase (KRYSTEXXA®) Treatment in Adult Patients with Chronic Gout Refractory to Conventional Therapy (Abstract # OP0113). This data will be presented in an oral presentation on Thursday, May 26, 2011 at 11:20 AM.
  • Quality of Life, Work Impairment and Resource Utilisation Associated with Gout and Its Co-Morbidities Across Five EU Countries: Results from the European National Health and Wellness Survey (NHWS) (Abstract # FRI0275-HP). This data will be presented during the EULAR poster session on Friday, May 27, 2011 at 11:45 AM.

Additional details on these abstracts are available on the EULAR website at http://www.eular.org/.  

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
2. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
3. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
4. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
5. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
6. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
7. Savient Closes Sale of $230 Million in Convertible Senior Notes
8. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
9. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
11. Savient Pharmaceuticals Announces Search for CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Dec. 9, 2016   Hudes Laser Aesthetica ... featuring the multi-wavelength Astanza Trinity laser and Astanza ... in laser tattoo removal, IPL hair removal, pigmented ... therapy. Hudes Laser Aesthetica is setting high standards ... and promises to deliver effective, long-lasting results. ...
(Date:12/9/2016)... , Dec 9, 2016 Research ... Transceiver Market 2016-2020" report to their offering. ... The report forecasts the global ... the period 2016-2020. The report covers the present ... for 2016-2020. To calculate the market size, the report considers the ...
(Date:12/9/2016)... 2016  Harmar Mobility, LLC announced today that Steven E. Dawson has ... Board of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles ... variety of industries. He brings to the company deep operational and leadership ...
Breaking Medicine Technology:
(Date:12/10/2016)... Aliso Viejo, California (PRWEB) , ... December 10, 2016 , ... ... editors to create dozens of unique animations," said Christina Austin - CEO of Pixel ... created exclusively for use within FCPX . This set of versatile transitions ...
(Date:12/10/2016)... ... December 10, 2016 , ... When faced with having ... germs spreading from the seat to her body, and contamination of children when they ... way to solve this problem that many people face. , The patent-pending SANI-POCKET enables ...
(Date:12/9/2016)... ... December 09, 2016 , ... Cellairis is a worldwide mobile device and ... iPhone , iPad and Samsung Galaxy devices with premium parts and accessories. ... to maximize convenience and accessibility for customers. While customers do their shopping, Cellairis can ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide ... Columbia as an education tool in the war against teen drug abuse. NCADD ...
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... Mediaplanet ... awareness for organ transplantation while encouraging readers to sign up as an organ donor ... lifesaving organ transplant. , An organ donor can save up to 8 saves ...
Breaking Medicine News(10 mins):